产品
编 号：F144924
分子式：C26H52N6O11S
分子量：656.79
分子式：C26H52N6O11S
分子量：656.79
产品类型
规格
价格
是否有货
100mg
询价
询价
500mg
询价
询价
结构图
CAS No: 138-14-7
产品详情
生物活性：
Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.
体内研究：
Deferoxamine mesylate (6.57 μg/小鼠；点滴；每天一次，持续 21 天) 促进老年或糖尿病小鼠的伤口愈合并增加新血管形成。Deferoxamine mesylate (200 mg/kg；腹腔注射；每天一次，持续 2 周) 导致 HIF-1α 稳定并增加葡萄糖摄取、肝脏 InsR 表达和体内信号传导。Animal Model:Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model).
Dosage:6.57 μg/per (10 uL of 1 mM)
Administration:Drip-on; once daily for 21 days.
Result:Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model.
Animal Model:Male Sprague-Dawley rats (180-200 g).
Dosage:200 mg/kg
Administration:Intraperitoneal injection; daily for 2 weeks.
Result:Significantly increased hepatic HIF-1α protein levels, InsR protein levels, as well as Akt/PKB and activated Akt/PKB were significantly higher in the liver.
体外研究：
Deferoxamine mesylate (1 mM；16 小时或 4 周) 改善低氧和高血糖条件下的 HIF-1α 功能并降低 MEF 细胞中的 ROS。 Deferoxamine mesylate (100 μM；24 h) 增加 InsR 表达和活性，并诱导 p-Akt/总 Akt/PKB 水平增加。去铁胺甲磺酸盐 (5、10、25、50、100 μM；7 或 9 天) 抑制肿瘤相关 MSC 和骨髓 MSC 的增殖。甲磺酸去铁胺 (5、10、25、50、100 μM；7 天) 诱导间充质干细胞凋亡。甲磺酸去铁胺 (10 μM；3天) 影响间充质干细胞粘附蛋白的表达。 Deferoxamine mesylate (100 μM；24 h) 在 SH-SY5Y 细胞中诱导由 HIF-1α 水平介导的自噬。
Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.
体内研究：
Deferoxamine mesylate (6.57 μg/小鼠；点滴；每天一次，持续 21 天) 促进老年或糖尿病小鼠的伤口愈合并增加新血管形成。Deferoxamine mesylate (200 mg/kg；腹腔注射；每天一次，持续 2 周) 导致 HIF-1α 稳定并增加葡萄糖摄取、肝脏 InsR 表达和体内信号传导。Animal Model:Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model).
Dosage:6.57 μg/per (10 uL of 1 mM)
Administration:Drip-on; once daily for 21 days.
Result:Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model.
Animal Model:Male Sprague-Dawley rats (180-200 g).
Dosage:200 mg/kg
Administration:Intraperitoneal injection; daily for 2 weeks.
Result:Significantly increased hepatic HIF-1α protein levels, InsR protein levels, as well as Akt/PKB and activated Akt/PKB were significantly higher in the liver.
体外研究：
Deferoxamine mesylate (1 mM；16 小时或 4 周) 改善低氧和高血糖条件下的 HIF-1α 功能并降低 MEF 细胞中的 ROS。 Deferoxamine mesylate (100 μM；24 h) 增加 InsR 表达和活性，并诱导 p-Akt/总 Akt/PKB 水平增加。去铁胺甲磺酸盐 (5、10、25、50、100 μM；7 或 9 天) 抑制肿瘤相关 MSC 和骨髓 MSC 的增殖。甲磺酸去铁胺 (5、10、25、50、100 μM；7 天) 诱导间充质干细胞凋亡。甲磺酸去铁胺 (10 μM；3天) 影响间充质干细胞粘附蛋白的表达。 Deferoxamine mesylate (100 μM；24 h) 在 SH-SY5Y 细胞中诱导由 HIF-1α 水平介导的自噬。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备